Hims & Hers: A Critical Week for a Stock Riding a Regulatory Wave

Hims & Hers stock soared 37% on FDA peptide review hopes, but Q1 earnings face headwinds from revenue delays, margin pressure, and a data breach lawsuit.

Investors in telehealth provider Hims & Hers are bracing for a pivotal week, caught between a powerful regulatory tailwind and significant operational headwinds. The stock’s recent surge of nearly 37% in a single week, culminating in an 11% jump to around $27 on Thursday alone, has set the stage for a crucial earnings report that will test the rally’s foundations.

The catalyst for the explosive move was a signal from Washington. US Health Secretary Robert F. Kennedy Jr. indicated that the Food and Drug Administration (FDA) plans to re-evaluate its strict rules for a group of peptide compounds. An expert advisory committee is scheduled to discuss the potential loosening of restrictions in July, which could allow pharmacies to compound these substances for individual patients. For Hims & Hers, which acquired a peptide manufacturing facility in February 2025 and views the technology as central to its future, the news was a timely boost.

This regulatory optimism, however, starkly contrasts with the company’s immediate financial reality. Management has officially confirmed it will release first-quarter 2026 results after the US market closes on May 11, followed by a conference call. The guidance provided is sobering. Hims & Hers expects Q1 revenue to land between $600 million and $625 million, but acknowledges a significant $65 million revenue shift into the second quarter due to timing changes in shipments. This strategic pivot in its US weight-loss business is proving costly.

The company is fundamentally restructuring this segment, moving away from prescribing compounded semaglutid and prioritizing the branded drug Wegovy instead. Beyond the revenue delay, margins are under pressure from international expansion and lingering uncertainty around regulated GLP-1 medications. Adjusted EBITDA for the quarter is projected to be between $35 million and $55 million. The strain was already visible in Q4 2025, when free cash flow turned negative.

Adding to the operational challenges is a legal threat stemming from a data breach. In early February 2026, a cyberattack on external service provider Zendesk compromised Hims & Hers customer support tickets. While the company states medical records were not accessed, attackers obtained names and contact information. Several law firms are now preparing class-action lawsuits, creating a potential distraction and financial liability.

Wall Street’s view is divided. The recent regulatory news has prompted some bullish calls; Bank of America raised its price target to $25, and analysts at Leerink see peptides as a major opportunity that could fill a potential revenue gap from weight-loss injections. Yet, the elevated short interest and the upcoming Q1 results underscore persistent concerns about valuation and near-term profitability.

The full-year 2026 outlook remains ambitious, targeting revenue of $2.7 billion to $2.9 billion—a 59% increase over the approximately $2.35 billion expected for 2025—and adjusted EBITDA of $300 million to $375 million. Achieving these goals hinges on the Q1 disruption being merely a timing issue. Investors will seek clarity not only on the earnings call but also at the Evercore TMT Conference in San Francisco on June 2, where management is scheduled to present.

Technically, the stock’s break above its 50-day moving average provided an initial buy signal, with the next resistance level at the 100-day line. Yet, the fundamental direction will likely be defined later this summer. The FDA committee’s decision in July on new peptide rules will ultimately shape the company’s long-term growth strategy, determining whether the recent rally was a fleeting fantasy or the start of a sustainable new path.